Investment Type: Venture Capital
Portfolio 2
| Date | Name | Website | Total Raised | Location |
| 08.09.2025 | NRG Therap... | nrgtherapeutics.com | $86.46M | United Kin... |
| 28.08.2025 | Vaxxas | vaxxas.com | $128.76M | Australia |
Mentions in press and media 18
| Date | Title | Description |
| 08.09.2025 | NRG Therapeutics secures £50M Series B to advance mitochondrial drugs for ALS and Parkinson’s | Stevenage-based biotech startup NRG Therapeutics has closed a £50 million Series B funding round as it moves towards clinical trials for its pipeline of treatments targeting mitochondrial dysfunction in neurodegenerative diseases. The round... |
| 08.09.2025 | NRG Therapeutics Raises £50M Series B Financing | NRG Therapeutics, a Stevenage, UK-based neuroscience company targeting a novel mechanism to address mitochondrial dysfunction, raised £50M in Series B funding. The round was led by Health Investors’ Dementia Discovery Fund, alongside other ... |
| 28.08.2025 | Vaxxas: A$90 Million Secured For Commercializing Needle-Free Vaccination Delivery Technology | Vaxxas, a biotechnology company developing the high-density microarray patch (HD-MAP) for needle-free vaccine delivery, has secured approximately $90 million in its latest financing round. This funding, one of the largest in Australia for a... |
| 28.07.2025 | Brandon Capital: Fund Six Closed At Over A$439 Million | Brandon Capital, Australasia’s leading life sciences venture capital firm, has announced the final close of its sixth fund, the Brandon BioCatalyst Fund Six (BB6), totaling A$439 million. New investors in BB6 include the Western Australia G... |
| 28.07.2024 | CatalYm's $150 Million Bet on Cancer Resistance: A New Dawn in Immunotherapy | In the relentless battle against cancer, CatalYm has emerged as a beacon of hope. The Munich-based company recently secured $150 million in Series D funding, a significant leap forward in its mission to combat cancer therapy resistance. Thi... |
| 27.07.2024 | CatalYm: Cancer Therapy Resistance Mechanism Company Raises $150 Million In Series D | CatalYm announced the completion of a $150 million Series D financing. The oversubscribed funding round was led by new investors, Canaan Partners and Bioqube Ventures, and joined by Forbion’s Growth Opportunities Fund, Omega Funds and Gilde... |
| 09.06.2022 | Amaroq Therapeutics hits early milestones and makes key appointments to Scientific Advisory Board | Promising 'dark matter' cancer therapy has clinical trials in sight DUNEDIN, New Zealand, June 9, 2022 /PRNewswire/ -- Amaroq Therapeutics, a biotechnology company focussed on developing a new class of therapeutics that target lncRNA in can... |
| 15.06.2021 | ENA Respiratory Advances COVID-19 Preventative Therapy through AU$32 Million Funding Round | Round jointly led by Brandon Capital and Minderoo Foundation with co-investment from Uniseed will support the clinical development of INNA-051 Company appoints President and Chief Scientific Officer of the COPD Foundation and respiratory th... |
| 28.09.2020 | Preventative nasal spray shown to reduce viral replication by up to 96% in COVID-19 challenge study | New preventative nasal spray treatment that could protect people from COVID-19 infection and prevent transmission announced Novel therapy developed by Australian biotech company, Ena Respiratory, shown to significantly reduce COVID-19 virus... |
| 12.06.2020 | Glyscend Therapeutics Completes $20.5 M Series A | Glyscend Therapeutics, a privately held biopharmaceutical company developing novel treatments for type 2 diabetes (T2D) and related metabolic conditions, today announced the closing of a $20.5 million Series A financing round. Healthcare in... |
Show more